A Phase I/II Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma Relapsed From or Refractory to Bortezomib
Multiple myeloma is a bone marrow based malignancy of plasma cells that is highly treatable
but rarely curable. Angiogenesis, defined as the growth of new blood vessels from
pre-existing vessels, is a requirement for the growth of nearly all tumors. An increase in
bone marrow angiogenesis is present in Multiple Myeloma and correlates with disease
progression. Several new therapies that target angiogenic pathways have shown clinical
efficacy. ATN-224 is a small molecule that has been shown in pre-clinical studies to be
antiangiogenic.
Using one agent to overcome resistance of another agent is a treatment regimen used in
oncology. A preclinical study with the combination of ATN-224 and bortezomib shows that the
combination is more effective than either single agent in a bortezomib resistant cell line.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: Determine a safe dose of ATN-224 and bortezomib to be used in the phase II portion of the study
Ongoing
Yes
Gilad Gordon, MD
Study Director
United States: Food and Drug Administration
ATN-224-007
NCT00352742
June 2006
December 2008
Name | Location |
---|---|
Roswell Park Cancer Institute | Buffalo, New York 14263 |
Florida Cancer Specialists | Fort Myers, Florida 33901 |
Mary Crowley Medical Research Center | Dallas, Texas 75246 |
Tyler Cancer Center | Tyler, Texas 75702 |
The Cancer Institute of New Jersey | New Brunswick, New Jersey 08901 |
Center for Cancer and Blood Disorders | Bethesda, Maryland 20817 |
Billings Clinic | Billings, Montana 59107-7000 |
Hematolgy-Oncology Medical Group of Fresno, Inc. | Fresno, California 93720 |
Institute for Myeloma and Bone Cancer Research | West Hollywood, California 90069 |
SUNY Downstate | Brooklyn, New York 11203 |